Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2004 2
2005 4
2006 14
2007 15
2008 16
2009 32
2010 57
2011 71
2012 84
2013 97
2014 83
2015 81
2016 78
2017 128
2018 111
2019 92
2020 102
2021 132
2022 125
2023 126
2024 144
2025 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,429 results

Results by year

Filters applied: . Clear all
Page 1
The adverse-effect profile of lacosamide.
Li J, Sun M, Wang X. Li J, et al. Expert Opin Drug Saf. 2020 Feb;19(2):131-138. doi: 10.1080/14740338.2020.1713089. Epub 2020 Jan 15. Expert Opin Drug Saf. 2020. PMID: 31914330 Review.
Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe and Asia since it was approved by the FDA in 2008. ...The review showed that lacosamide is safe and effective in antiepileptic treatment, and its common side effects are dizzine …
Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe and Asia since it was approved by the FDA in …
Lacosamide in status epilepticus: Systematic review of current evidence.
Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, Rosenow F, Bauer S. Strzelczyk A, et al. Epilepsia. 2017 Jun;58(6):933-950. doi: 10.1111/epi.13716. Epub 2017 Mar 11. Epilepsia. 2017. PMID: 28295226 Review.
OBJECTIVE: The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epilepticus (SE). ...The main adverse events during treatment of SE are dizziness, abnormal vision, diplopia, and ataxia. Overall, lacosamide …
OBJECTIVE: The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epile …
Lacosamide.
Doty P, Rudd GD, Stoehr T, Thomas D. Doty P, et al. Neurotherapeutics. 2007 Jan;4(1):145-8. doi: 10.1016/j.nurt.2006.10.002. Neurotherapeutics. 2007. PMID: 17199030 Free PMC article. Review.
In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently reported adverse events (> or =10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double-blind, double-du …
In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently repo …
Lacosamide add-on therapy for focal epilepsy.
Babar RK, Bresnahan R, Gillespie CS, Michael BD. Babar RK, et al. Cochrane Database Syst Rev. 2021 May 17;5(5):CD008841. doi: 10.1002/14651858.CD008841.pub3. Cochrane Database Syst Rev. 2021. PMID: 33998660 Free PMC article.
We contacted UCB Pharma (sponsors of lacosamide). SELECTION CRITERIA: Randomised controlled trials of add-on lacosamide in people with drug-resistant focal epilepsy. ...Higher doses of lacosamide may be associated with higher rates of adverse events and treat …
We contacted UCB Pharma (sponsors of lacosamide). SELECTION CRITERIA: Randomised controlled trials of add-on lacosamide in peo …
Lacosamide and pregnancy: Data from spontaneous and solicited reports.
Perucca P, Bourikas D, Voinescu PE, Vadlamudi L, Chellun D, Kumke T, Werhahn KJ, Schmitz B. Perucca P, et al. Epilepsia. 2024 May;65(5):1275-1284. doi: 10.1111/epi.17924. Epub 2024 Feb 27. Epilepsia. 2024. PMID: 38411300
Data are limited on pregnancy outcomes among patients taking lacosamide (LCM), particularly when taken as monotherapy. The objective of this analysis was to evaluate the pregnancy outcomes of LCM-exposed pregnancies. ...
Data are limited on pregnancy outcomes among patients taking lacosamide (LCM), particularly when taken as monotherapy. The objective …
Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy.
Hoy SM. Hoy SM. CNS Drugs. 2018 May;32(5):473-484. doi: 10.1007/s40263-018-0523-7. CNS Drugs. 2018. PMID: 29785508 Review.
Moreover, patients were effectively switched from adjunctive oral lacosamide to the same dosage of intravenous lacosamide. Oral lacosamide was an effective conversion to monotherapy agent in this patient population and as monotherapy demonstrated noninferiori …
Moreover, patients were effectively switched from adjunctive oral lacosamide to the same dosage of intravenous lacosamide. Ora …
[Lacosamide (vimpat). Prospects for clinical application].
Rudakova IG, Vlasov PN, Lipatova LV, Voronkova KV. Rudakova IG, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):147-152. doi: 10.17116/jnevro201711791147-152. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 29053136 Review. Russian.
This article presents the review of the most significant studies of the efficacy and tolerability of lacosamide (LCM) in treatment of patients with focal epilepsy. The review includes the results of the main studies which preceded the official approval of LCM use in mono- …
This article presents the review of the most significant studies of the efficacy and tolerability of lacosamide (LCM) in treatment of …
Lacosamide: in partial-onset seizures.
Cross SA, Curran MP. Cross SA, et al. Drugs. 2009;69(4):449-59. doi: 10.2165/00003495-200969040-00005. Drugs. 2009. PMID: 19323588 Review.
Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosamide has been established. The bioavailability of the oral lacosamide tablet was similar to that of a 30- or 60-minute intravenous …
Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosami …
Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases.
Muñoz-Vendrell A, Teixidor S, Sala-Padró J, Campoy S, Huerta-Villanueva M. Muñoz-Vendrell A, et al. Cephalalgia. 2022 Sep;42(10):1031-1038. doi: 10.1177/03331024221092435. Epub 2022 Apr 26. Cephalalgia. 2022. PMID: 35469475 Free PMC article. Review.
The aim of this descriptive study was to evaluate the effectiveness and security of intravenous lacosamide and phenytoin in the treatment of acute trigeminal neuralgia pain. METHODS: We reviewed patients who attended the emergency department of a tertiary hospital between …
The aim of this descriptive study was to evaluate the effectiveness and security of intravenous lacosamide and phenytoin in the treat …
Lacosamide.
Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Perucca E, et al. Nat Rev Drug Discov. 2008 Dec;7(12):973-4. doi: 10.1038/nrd2764. Nat Rev Drug Discov. 2008. PMID: 19043448
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. ...
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for pa …
1,429 results